Plain-English translation of NCT07186842 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This trial is testing a new immunotherapy drug called in people with advanced cancers that express a marker called CA19-9 and haven't responded well to previous treatments. The study will first test different doses and schedules of the medication to understand how safe it is and how often people should receive it. Then, researchers will test whether the medication actually helps shrink tumors in people with pancreatic cancer.
Advanced cancers that no longer respond to standard treatments are extremely difficult to treat, and patients have few options left. This trial exists to see if this new immunotherapy approach can help people with these hard-to-treat cancers by training their immune system to recognize and attack cancer cells.
You likely qualify if…
You likely don't qualify if…
You will visit a research clinic regularly to receive injections of the medication—either once every 3 weeks or once every 2 weeks, depending on which part of the study you join. The treatment period lasts up to 2 years, during which you'll have blood tests, scans, and check-ins to monitor how the medication is working and any side effects. After treatment ends, you'll have follow-up visits to check on your health and safety, and researchers will continue to track your survival over time.
AI-generated summary from trial data · Sep 2, 2026 · Not medical advice
United States
Australia